论文部分内容阅读
目的观察辛伐他汀对血脂正常高血压患者炎症因子高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)水平的影响。方法选择2008年1月-2010年6月在武警湖北省总队医院心血管内科门诊或住院的符合标准的血脂正常高血压患者120例,随机分为对照组(60例)与治疗组(60例),对照组患者予非洛地平缓释片治疗,治疗组患者在予非洛地平缓释片治疗基础上加服辛伐他汀(20 mg/d),治疗12周。分别于治疗前后检测患者血压及血清hs-CRP、TNF-α和IL-6水平。结果治疗前两组患者血压及血清hs-CRP、TNF-α和IL-6水平比较,差异无统计学意义(P均>0.05)。治疗12周后,两组患者血压及血清hs-CRP、TNF-α和IL-6水平均比治疗前明显降低(P均<0.01),但治疗组下降更显著,与对照组比较,差异有统计学意义(P<0.05或P<0.01)。结论辛伐他汀对血脂正常高血压患者能协同降压,抑制炎症反应,从而有益于血压的控制。
Objective To observe the effects of simvastatin on the levels of hs-CRP, TNF-α and interleukin-6 in patients with lipid-induced hypertension. Methods A total of 120 patients with obesity and normal blood pressure were enrolled in the Department of Cardiology of the Armed Police Corps Hospital of Hubei Province from January 2008 to June 2010. They were randomly divided into control group (60 cases) and treatment group (60 cases ). Patients in the control group were treated with sustained-release tablets of felodipine. Patients in the treatment group were given simvastatin (20 mg / d) for 12 weeks on the basis of sustained-release tablets of felodipine. Blood pressure, serum hs-CRP, TNF-α and IL-6 levels were measured before and after treatment. Results There were no significant differences in blood pressure, serum hs-CRP, TNF-α and IL-6 levels between the two groups before treatment (all P> 0.05). After 12 weeks of treatment, the levels of blood pressure and serum hs-CRP, TNF-α and IL-6 in both groups were significantly lower than those before treatment (all P <0.01), but the treatment group decreased more significantly. Compared with the control group, Statistical significance (P <0.05 or P <0.01). Conclusion Simvastatin can reduce blood pressure and suppress inflammation in patients with normal blood pressure, which is beneficial to the control of blood pressure.